Oculis Announces Public Listing After Completing Business Combination Between European Biotech Acquisition Corp. And Oculis SA

Photography courtesy of Nasdaq, Inc.

CFGI’s Capital Markets team assisted Oculis Holding AG (“Oculis”) with its listing on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”) and Oculis SA.

Oculis’ shares began trading on the Nasdaq Stock Market under the ticker symbol “OCS” on March 3, 2023. 

Oculis is a global biopharmaceutical company (NASDAQ: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease-modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.

The CFGI team was led by Chris Brandes (Capital Markets). For further information, please read Oculis’ press release.